The present invention relates to a IL-1 antagonist alone or in combination with other therapeutic agents and relative pharmaceutical compositions for use for the treatment and/or prevention of toxicity induced by a T cell therapy, wherein the T cell expresses at least one recombinant receptor.

The present invention relates to a recombinant herpes simplex virus (HSV) containing an expression cassette capable of expressing a fused protein of a cancer-cell-targeting domain and an extracellular domain of HVEM and the use thereof. When the recombinant HSV infects and enters target cells, which are cancer cells, HSV proliferates, and an adapter, which is the fused protein, is expressed in the cells and is released to the outside of the cells along with the proliferated HSV virion upon cell lysis, or is released even before the virion is released due to cell lysis when the adapter contains a leader sequence, and the fused protein released to the outside of the cells acts to induce the HSV virion to infect surrounding cancer cells expressing a target molecule recognized by the cancer-cell-targeting domain or to increase the infection efficiency thereof.

The invention provides vector compositions for delivering improved adoptive T cell therapies.

The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid.

Methods and systems for diagnosing, providing prophylaxis, and treating one or more age-related neurodegeneration or pathological cognitive impairment are provided. An increased presence of CD103+ resident memory CD8+ T cells (CD8+ T.sub.RM) can be detected in blood sample obtained from the human subjects with one or more symptoms of loss of short-term or long-term memory, decreased ability to maintain focus, and decreased problem-solving capacity. An increased presence of CD103+ CD8+ T.sub.RM can be compared to a value obtained from one or a pool of healthy human subjects with none of the one or more symptoms. One or more of a therapeutically effective amount of: an inhibitor of cluster of differentiation (CD103), an inhibitor of perforin-1, and an inhibitor of interferon gamma (IFN) can be administered as treatment of age-related neurodegeneration or pathological cognitive impairment. Pathological neurodegeneration can include Parkinson's disease, multiple sclerosis, or Alzheimer' s disease.

The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.

Vector compositions comprising a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to a chimeric antigen receptor (CAR) are provided.

The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid.

The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.